Target type: biologicalprocess
The directed movement of a ceramide 1-phosphate into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. [GOC:TermGenie, PMID:23863933]
Ceramide 1-phosphate (C1P) transport is a complex process that involves the movement of this bioactive lipid across cellular membranes. C1P is a crucial signaling molecule involved in various cellular processes, including cell growth, differentiation, apoptosis, and inflammation. The exact mechanisms of C1P transport are still under investigation, but several proteins and pathways have been implicated.
One prominent player in C1P transport is the lipid transporter ABCA1. This protein is known to transport various lipids, including C1P, from the inner leaflet of the plasma membrane to the outer leaflet. ABCA1-mediated C1P transport is thought to be important for regulating cellular C1P levels and mediating its signaling functions.
Another key component of C1P transport is the sphingolipid transporter protein CERT. This protein facilitates the transport of C1P from the endoplasmic reticulum (ER) to the Golgi apparatus, where it is further processed and utilized. CERT plays a crucial role in the biosynthesis of complex sphingolipids, which are essential for cell membrane structure and function.
In addition to these specific proteins, other mechanisms contribute to C1P transport. Vesicular trafficking, a process involving the movement of cellular components within membrane-bound vesicles, is also involved in the transport of C1P. These vesicles can transport C1P from the ER to other cellular compartments, including the plasma membrane and lysosomes.
Furthermore, C1P can be transported across cellular membranes via diffusion. This passive transport mechanism is likely to play a role in the movement of C1P across short distances within the cell.
The specific mechanisms of C1P transport can vary depending on the cell type and the cellular context. For example, in neurons, C1P transport may be involved in the regulation of neuronal survival and axonal growth. In immune cells, C1P transport may be involved in the regulation of inflammatory responses.
Overall, C1P transport is a multifaceted process that involves the coordinated action of multiple proteins and pathways. It plays a crucial role in regulating C1P signaling and ensuring the proper functioning of various cellular processes.'
"
| Protein | Definition | Taxonomy |
|---|---|---|
| Microsomal triglyceride transfer protein large subunit | A microsomal triglyceride transfer protein large subunit that is encoded in the genome of human. [PRO:HJD, UniProtKB:P55157] | Homo sapiens (human) |
| Compound | Definition | Classes | Roles |
|---|---|---|---|
| nevirapine | nevirapine : A dipyridodiazepine that is 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepine which is substituted by methyl, oxo, and cyclopropyl groups at positions 4, 6, and 11, respectively. A non-nucleoside reverse transcriptase inhibitor with activity against HIV-1, it is used in combination with other antiretrovirals for the treatment of HIV infection. Nevirapine: A potent, non-nucleoside reverse transcriptase inhibitor used in combination with nucleoside analogues for treatment of HIV INFECTIONS and AIDS. | cyclopropanes; dipyridodiazepine | antiviral drug; HIV-1 reverse transcriptase inhibitor |
| efavirenz | efavirenz : 1,4-Dihydro-2H-3,1-benzoxazin-2-one substituted at the 4 position by cyclopropylethynyl and trifluoromethyl groups (S configuration) and at the 6 position by chlorine. A non-nucleoside reverse transcriptase inhibitor with activity against HIV, it is used with other antiretrovirals for combination therapy of HIV infection. efavirenz: HIV-1 reverse transcriptase inhibitor | acetylenic compound; benzoxazine; cyclopropanes; organochlorine compound; organofluorine compound | antiviral drug; HIV-1 reverse transcriptase inhibitor |
| bms201038 | BMS201038: an anticholesteremic agent and microsomal triglycide transfer protein inhibitor lomitapide : A member of the class of benzamides obtained by formal condensation of the carboxy group of 4'-(trifluoromethyl)biphenyl-2-carboxylic acid with the primary amino group of 9-[4-(4-aminopiperidin-1-yl)butyl]-N-(2,2,2-trifluoroethyl)-9H-fluorene-9-carboxamide. Used (as its mesylate salt) as a complement to a low-fat diet and other lipid-lowering treatments in patients with homozygous familial hypercholesterolemia. | (trifluoromethyl)benzenes; benzamides; fluorenes; piperidines | anticholesteremic drug; MTP inhibitor |
| dirlotapide | dirlotapide: structure in first source | ||
| jnj-31020028 |